Chimerix
Chimerix, Inc. is a development-stage biopharmaceutical company based in Durham, North Carolina, focused on creating innovative antiviral therapies and treatments for serious diseases, particularly in oncology and transplant settings. The company’s lead candidate, CMX001, is being investigated as a broad-spectrum antiviral for life-threatening double-stranded DNA viral infections, with clinical studies demonstrating its efficacy and safety in immunocompromised patients. In addition to CMX001, Chimerix is developing CMX157, a nucleoside analogue targeting HIV and hepatitis B, which has shown promise in early trials. Chimerix has established various partnerships and licensing agreements with organizations such as the Biomedical Advanced Research and Development Authority and Cantex Pharmaceuticals, facilitating the development of its compounds. The company also aims to address global health challenges, leveraging its extensive chemical library to explore new treatments for diseases like hepatitis C and malaria. Founded in 2000, Chimerix continues to advance its clinical programs to improve patient outcomes in critical care contexts.
Oncoceutics, Inc. is a clinical-stage drug discovery and development company based in Philadelphia, Pennsylvania, founded in 2009. The company focuses on developing therapeutics that target critical signaling pathways in cancer. Its lead compound, ONC201, is an orally active DRD2 small molecule antagonist known for its significant anti-tumor activity across various cancer types through a unique mechanism of action. ONC201 has demonstrated compelling preclinical efficacy and a favorable safety profile, making it a promising candidate for clinical use. The company is actively conducting clinical trials for ONC201 at leading cancer centers globally, aiming to provide safe and effective treatment options for patients with advanced cancers. Additionally, Oncoceutics maintains strategic alliances with organizations such as the National Institutes of Health and Calvert Research, LLC, to enhance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.